Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Antares Pharma (NQ: ATRS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 5.590 (55)
Ask (Size) 5.600 (261)
Prev. Close 5.590
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 170,579,682
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into Antares Pharma's Return On Invested Capital
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter. 
Via Benzinga
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

More News

Read More
ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS
From Kuznicki Law PLLC
Via Business Wire
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS
From Kahn Swick & Foti, LLC
Via Business Wire
Antares Pharma's Oral Testosterone Treatment Scores FDA Approval
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Via Benzinga
Looking Into Antares Pharma Inc's Recent Short Interest
Via Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
Via InvestorPlace
Why Antares Pharma Stock Is Soaring Today
Via Benzinga
Why Is BriaCell (BCTX) Stock Moving Today?
Via InvestorPlace
Why Is Antares Pharma (ATRS) Stock Up Today?
Via InvestorPlace
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More
Via Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
Via Investor's Business Daily
Futures Rise As Earnings Season Begins
Via Talk Markets
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Via Benzinga
ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13
Via Benzinga
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
Antares Pharma's Return On Capital Employed Overview
Via Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.